Prosecution Insights
Last updated: July 05, 2026
Application No. 17/908,291

NEW METHOD AND COMPOUND FOR PROSTATE CANCER DIAGNOSIS

Final Rejection §101
Filed
Aug 31, 2022
Priority
Mar 03, 2020 — EU 20160712.4 +1 more
Examiner
AEDER, SEAN E
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Prosmedic Sweden AB
OA Round
2 (Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
802 granted / 1413 resolved
-3.2% vs TC avg
Strong +20% interview lift
Without
With
+19.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
67 currently pending
Career history
1488
Total Applications
across all art units

Statute-Specific Performance

§101
15.1%
-24.9% vs TC avg
§103
32.6%
-7.4% vs TC avg
§102
12.4%
-27.6% vs TC avg
§112
17.9%
-22.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1413 resolved cases

Office Action

§101
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action The Amendments and Remarks filed 3/26/26 in response to the Office Action of 1/8/26 are acknowledged and have been entered. Claims 31-39 have been added by Applicant. Claims 12-16, 18, 23, 25, 27, and 31-39 are pending. Claims 12-16, 18, 23, 25, and 27 have been amended by Applicant. Claims 12-16, 18, 23, 25, 27, and 31-39 are currently under examination. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The following Office Action contains NEW GROUNDS of rejections Necessitated by Amendments. Rejections Withdrawn All previous rejections are withdrawn. New Rejections Necessitated by Amendments Claim Rejections - 35 USC § 101 Claims 16, 23, 25, 27, and 33-38 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because the claims do not recite a process, machine, manufacture, or composition of matter. The claims do not fall within at least one of the four categories of patent eligible subject matter because a combination of steps of solely “comparing” and “determining” is not a process, machine, manufacture, or composition of matter. See MPEP 2106.03 The claimed combinations of steps of solely “comparing” and “determining” is not a “process”/method because it is not an act or step, a series of acts or steps, a mode of treatment of certain materials to produce a given result, or an act, or a series of acts, performed upon subject-matter to be transformed and reduced to a different state or thing. The claimed combinations of steps of solely “comparing” and “determining” is not a “machine” because it is not a concrete thing, consisting of parts, or of certain devices and combination of devices. The claimed combinations of steps of solely “comparing” and “determining” is not a “manufacture” because it is not a tangible article. The claimed combinations of steps of solely “comparing” and “determining” is not a “composition of matter” because it is not a combination of two or more substances. Claim Rejections - 35 USC § 101 Claim 16, 23, 25, 27, and 33-38 are rejected under 35 U.S.C. 101 because the claimed invention is directed to judicial exception(s) (i.e., a law of nature, a natural phenomenon, and/or an abstract idea) without significantly more. Abstract ideas include mathematical concepts (including mathematical relationships, formulas, equations, and calculations), mental processes (including concepts performed in the human mind), and certain methods of organizing human activity (including managing personal behavior, relationships, or interactions between people). The rationale for this determination is explained below: Claims 16, 23, 25, 27, and 33-38 are directed to abstract ideas because the claims recite an abstract idea (“Step 2A prong one”) and the judicial exception(s) is/are not integrated into a practical application (“Step 2A prong two”). The “abstract idea” is: a combination of comparing and determining steps (mental processes). The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception(s). A claim that focuses on judicial exception(s) can be shown to recite something “significantly more” than the judicial exception(s) by reciting a meaningful limitation beyond the judicial exceptions. However, in the instant case, the claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the claim is solely limited to performing abstract ideas (“Step 2B”). Allowable Subject Matter Claims 12-15, 18, 31, 32, and 39 are allowed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN E AEDER whose telephone number is (571)272-8787. The examiner can normally be reached M-F 9am-6pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SEAN E AEDER/ Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Aug 31, 2022
Application Filed
Nov 04, 2025
Non-Final Rejection (signed) — §101
Jan 08, 2026
Non-Final Rejection mailed — §101
Mar 26, 2026
Response Filed
Apr 30, 2026
Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12669505
DETECTION OF DESMOGLEIN-2 IN CANCERS OF EPITHELIAL ORIGIN
4y 2m to grant Granted Jun 30, 2026
Patent 12667616
Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
9m to grant Granted Jun 30, 2026
Patent 12656350
METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING A SAGE1-RELATED CONDITION
4y 0m to grant Granted Jun 16, 2026
Patent 12631644
BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION
4y 1m to grant Granted May 19, 2026
Patent 12629396
APPLICATION OF BACTERIA IN PREPARATION OF SYNERGIST FOR IMMUNE CHECKPOINT INHIBITOR
3y 2m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
77%
With Interview (+19.9%)
3y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1413 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month